ABSTRACT
The COVID-19 outbreak in Xinfadi (XFD) Wholesale market in Beijing, China in June, 2020 caused 368 reported cases within 39 days. Genetic evidences indicated that imported SARS-CoV-2 (belong to the lineage B1.1.29) initiated this outbreak. However, the transmission route of the virus is still unknown. We obtained from public database three SARS-CoV-2 genomes isolated in XFD (XFD genomes) and adopted the leaf-dating method to calculate their expected collection dates using temporal calibrating information from other 241 genomes collected in mainland of China. All three XFD genomes were calculated to have earlier collection dates than the recorded (Bayes factor >1), and hence exhibited a lack of genetic divergence. We additionally combined the XFD genomes with other 225 genomes subsampled from those of the lineage B1.1.29, among which five sequences were also included for control analysis. Two of three XFD genomes were calculated to have earlier collection dates than the recorded (Bayes factor >1), while no control genomes provided such evidence. According to present understanding of SARS-CoV-2, a lack of genetic divergence is most likely due to being frozen. Considering the fact that the XFD outbreak started from a booth of frozen food, we judged that the XFD outbreak was caused by contaminated frozen food. Our results provided molecular evidence for the source of COVID-19 outbreak in Beijing XFD, which highlights new targets for SARS-CoV-2 surveillance for the public health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported from the National Natural Science Foundation of China (Grant number: 82041023), the Bill & Melinda Gates Foundation (Grant number: INV-016826) and China Mega-Projects for Infectious Disease (2018ZX10711001, 2017ZX10104001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the paper.
